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Abstract
Background:  Acute vigorous exercise, associated with increased release of plasma
catecholamines, transiently increases the risk of primary cardiac arrest. We tested the effect of
acute submaximal exercise on vasoactive substances and their combined result on platelet function.
Methods: Healthy volunteers, hypertensive patients and patients with coronary artery disease
(CAD) performed a modified treadmill exercise test. We determined plasma catecholamines,
thromboxane A2, prostacyclin, endothelin-1 and platelet aggregation induced by adenosine
diphosphate (ADP) and collagen at rest and during exercise.
Results: Our results during exercise showed a) platelet activation (increased thromboxane B2,
TXB2), b) increased prostacyclin release from endothelium and c) decreased platelet aggregation
in all groups, significantly more in healthy volunteers than in patients with CAD (with hypertensives
lying in between these two groups).
Conclusion:  Despite the pronounced activation of Sympathetic Nervous System (SNS) and
increased TXB2  levels during acute exercise platelet aggregation decreases, possibly to
counterbalance the prothrombotic state. Since this effect seems to be mediated by the normal
endothelium (through prostacyclin and nitric oxide), in conditions characterized by endothelial
dysfunction (hypertension, CAD) reduced platelet aggregation is attenuated, thus posing such
patients in increased risk for thrombotic complications.
Background
Platelet aggregation and thrombosis play a central role in
the pathogenesis of atherosclerosis, since platelet aggre-
gates and thrombus formation has been found in the cor-
onary arteries at sites of plaque rupture [1]. Platelets, upon
their activation, further stimulate thrombus formation
and recruit additional platelets by releasing thromboxane
A2 (TXA2), adenosine diphosphate (ADP), and cytokines,
which produce and promote surface thrombin generation
and release vasoconstrictor substances [2]. Arterial hyper-
tension, apart from being a major risk factor for athero-
sclerotic coronary artery disease, is characterized by an
increased thrombotic tendency (the thrombotic paradox
of hypertension or 'Birmingham paradox') with evidence
of platelet activation, hypercoagulation and endothelial
dysfunction [3]. Platelet dysfunction has attired attention
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as a potential cause of increased cardiovascular morbidity
and mortality in essential hypertension [4]. All the above
suggest the importance of platelet function in coronary
artery disease and hypertension.
Platelet function is regulated by several factors that exhibit
opposing effects, and the dynamic balance between pro-
thrombotic and anti-antithrombotic factors determines
health or thrombosis. Platelet activation is modulated by
the function of normal endothelium that exerts a protec-
tive antithrombotic effect through the production of nitric
oxide (NO) and prostacyclin (PGI2), substances that cause
vasodilatation and inhibit platelet aggregation [2].
Endothelial dysfunction leads to nitric oxide (NO) defi-
ciency which has been implicated in the underlying
pathobiology of many of these disorders (NO insuffi-
ciency states) [5]. Moreover, endothelin-1 (ET-1, a potent
vasoconscrictive substance released by the endothelium)
and plasma catecholamines play a major role in the
pathogenesis of acute ischemic events, and stimulate
platelet aggregation, thus exerting prothrombotic actions.
In contrast to regular physical exercise that beneficially
affects cardiovascular mortality [6], acute vigorous exer-
cise that is characteristically accompanied by sympathetic
nervous system (SNS) activation may trigger the occur-
rence of acute ischemic events [7]. Furthermore, epidemi-
ological studies show that acute ischemic events exhibit a
circadian rhythm coinciding with increased activity of the
SNS and increased platelet aggregation during early morn-
ing hours [8]. SNS activation and the subsequent rise of
plasma catecholamines result in increased platelet aggre-
gation (possibly by activating platelet α2-adrenergic recep-
tors), thus offering a possible explanation for the
association between SNS activation and acute ischemic
events [9].
Although several lines of evidence elucidate the function
of each one of these vasoactive substances (catecho-
lamines, TXA2, prostacyclin, and ET-1) in patients with
coronary artery disease, their dynamic interaction remains
largely unclarified. The aim of our study was to investigate
platelet aggregation during acute submaximal exercise
(representing SNS activation) in patients with coronary
artery disease and hypertension compared to normal vol-
unteers. Furthermore, we aimed at clarifying the potential
contribution of vasoactive substances (such as catecho-
lamines, thromboxane A2, prostacyclin and ET-1) on
platelet aggregation by the simultaneous determination of
these factors during acute exercise.
Methods
Study population
Our study population consisted of 60 subjects divided in
three groups. Group A consisted of 18 healthy volunteers.
They had never experienced signs or symptoms of coro-
nary artery disease, their blood pressure was within nor-
mal levels, and they had no other risk factors for
atherosclerosis (diabetes mellitus, hypercholesterolemia,
obesity, smoking), and no positive family history of
hypertension or coronary artery disease.
Group B consisted of 26 patients with essential hyperten-
sion (BP > 140/90 mmHg) according to current guidelines
(JNC-7 and ESH/ESC). Secondary hypertension was
excluded by clinical and, if appropriate, laboratory exam-
ination. All patients had recently diagnosed mild or mod-
erate hypertension, confirmed in consecutive visits, and
had never used antihypertensive drugs. Hypertensive
patients with other cardiovascular risk factors beyond
hypertension were excluded.
Group C consisted of 16 patients with known coronary
artery disease that were in stable condition for at least
three months. All patients were not on antiplatelet medi-
cation due to gastrointestinal problems.
Thus, we included three clearly discrete populations
(completely healthy individuals without any cardiovascu-
lar risk factor, pure hypertensives without additional risk
factors, and patients with overt coronary artery disease) in
order to avoid potential confounding factors that affect
platelet aggregation. The various number of subjects in
each group is ought to the difficulties observed in per-
forming study protocol.
Overall 144 subjects were screened and 78 of them were
eligible for and agreed to participate in the study. Sixty-six
patients were excluded from the study because they had
concomitant conditions, such as diabetes mellitus or
impaired glucose tolerance (21 patients), hyperlipidae-
mia (16 patients), smoking (18 subjects), extreme obesity
(9 subjects), or positive family history for coronary artery
disease or hypertension (10 subjects). The study protocol
was very strict and laborious, and several difficulties had
to be overtaken; thus, full compliance with protocol pro-
cedures was achieved in only 60 out of 78 individuals par-
ticipating in the study. Specifically, blood sampling
during treadmill exercise at all time points was not suc-
cessful in 8 subjects, platelet aggregation could not be
determined in 5 subjects due to technical difficulties, and
the simultaneous determination of all vasoactive sub-
stances at each time point was not possible in 5 patients
due to several technical factors. There were no statistically
significant differences in baseline characteristics between
the subjects excluded and the subjects participating in the
study.
All individuals were sedentary and were not exercising on
a regular basis. All subjects gave informed consent and theBMC Cardiovascular Disorders 2008, 8:11 http://www.biomedcentral.com/1471-2261/8/11
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procedures followed were in accordance with institutional
guidelines. The study was approved by the Hospital Ethics
Committee and was in accordance with the principles of
the Helsinki declaration.
Study protocol
All medications in the CAD group were stopped for at
least one week. The use of aspirin, non-steroid anti-
inflammatory drugs or other drugs that interfere with
platelet function was prohibited for two weeks.
Blood pressure was measured using a mercury sphyg-
momanometer, following standard methodology. Three
blood pressure recordings were obtained consecutively,
and blood pressure was determined as the mean of the
second and the third recording. Systolic blood pressure
was defined at the point of appearance of the sounds
(Korotkoff phase I), and diastolic blood pressure at the
point of disappearance of the sounds (Korotkoff phase V).
A treadmill exercise test (Studio 350/4, Kardiolin, Quin-
ton) was performed (modified protocol by Bruce) for 15
minutes with blood pressure and ECG monitoring. All
subjects completed the exercise test with no symptoms or
ECG signs of myocardial ischemia.
All tests were performed in the morning (8 am). With the
patient in the supine position an intravenous indwelling
catheter (18G) was inserted and normal saline (0.9%) was
infused at a rate of 1 ml/min during the test. Blood was
drawn with the ''two syringe" method. Samples were con-
sidered suitable for examination if blood flowed freely in
the syringe. In total 4 blood samples were drawn. The first
with the patient in the supine position just before the
treadmill exercise (45 minutes after the placement of the
intravenous catheter), the second sample was drawn after
the completion of the first stage of the exercise test (9
min), the third sample at the end of the exercise (15 min)
and the fourth in the recovery period with the subject in
the supine position for 10 min.
Methods
Platelet aggregation was determined by nephelometry
(method by Born). Blood was collected in tubes contain-
ing sodium citrate (0.11 M) in 9:1 ratio and centrifuged at
150 × g for 5 min. The resulting platelet-rich (PRP) plasma
was kept at room temperature for use within 1 h. The rest
of the blood was centrifuged at 1500 × g for 15 min and
platelet-poor plasma (PPP) was prepared. Platelet counts
were adjusted in each sample with the addition of homol-
ogous PPP to 250 ± 50 × 109/L. Platelet aggregation was
determined with a four-channel aggregometer (PAP-4
Bio/Data). Platelet aggregation was induced by 50 μl of
collagen and 50 μl of ADP to the final concentration of 10
μg/ml of collagen and 1 μM ADP. The aggregometer was
adjusted before each experiment so that PRP permitted no
light transmittance and the PPP permitted 100% light
transmittance. Aggregation was expressed as the maximal
percent change in light transmission from baseline, using
PPP as a 100% and PRP as 0% reference of aggregation at
the end of the recording time. Aggregation curves were
recorded for 4 min.
Samples for plasma catecholamine (noradrenaline-NA
and adrenaline-ADR) determination were collected in
prechiled tubes containing heparin as anticoagulant. Cat-
echolamines were measured with the use of High Per-
formance Liquid Chromatography with Electrochemical
Detector (HPLC-ECD).
Samples for plasma ET-1 determination were collected in
tubes containing tripotassium ethylenediamine tetra-ace-
tate (K3EDTA). Plasma ET-1 concentrations were deter-
mined by radioimmunoassay (Nichols Institute
Diagnostics, San Juan Capistrano, CA), after solid-phase
extraction on C14 columns, evaporation in vacuum-centri-
fuge, and reconstruction of the solid remainder.
Plasma prostacyclin is highly unstable so we measured the
stable product 6-Keto-PGF1a with a radioimmunoassay
(DRG Diagnostics). Plasma Thromboxane A2  is also
unstable, so we measured the stable metabolite TXB2 by
radioimmunoassay (DRG Diagnostics).
We also determined the ratio of 6-keto-prostaglandin-F1a
to thromboxane B2 as an index of the balance between
antiaggregatory Prostacyclin and pro-aggregatory Throm-
boxane A2.
Statistical analysis
Analysis was performed using the Statistical Package for
Social Sciences (SPSS) 11,5 for Windows (SPSS Inc., Chi-
cago, IL, USA). Results are presented as mean ± standard
deviation (mean ± SD). Statistical analyses were carried
out using the Independent samples t test and the Mann
Whitney U test to compare proportions between 2 differ-
ent groups, and the 2-tailed paired Student's test and the
Wilcoxon Signed Rank Test to compare proportions of the
same group in different instants. Values of p <0.05 were
considered statistically significant.
Results
The baseline characteristics of the three groups are pre-
sented in Table 1. Normal volunteers were younger, leaner
and had lower blood pressure than hypertensives and
patients with coronary artery disease.
Systolic blood pressure increased significantly in all three
groups during treadmill exercise, while diastolic remained
unchanged in patients with coronary artery disease orBMC Cardiovascular Disorders 2008, 8:11 http://www.biomedcentral.com/1471-2261/8/11
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hypertension and fell, though not significantly, in healthy
individuals. Blood pressure at all stages remained higher
in the patients with coronary artery disease and hyperten-
sion (groups A and B) than in the healthy individuals (Fig-
ure 1). The Double Product was determined in all patients
at the peak of exercise with no significant differences
between the three groups (Table 2). Heart rate at the end
of exercise as percentage of the maximum heart rate (pre-
dicted by an age based formula; maximum heart rate =
220-age) was determined and there were no significant
differences between the three groups (Table 2).
Plasma catecholamines increased significantly (p < 0.01)
in all groups during exercise. Plasma noradrenaline at rest
was higher in hypertensive patients (p < 0.01) and
patients with coronary artery disease (p < 0.05) compared
to healthy individuals. At exercise peak plasma noradren-
aline increased about 10-fold, and hypertensives had
higher noradrenaline levels than normal subjects (p <
0.01) and coronary patients (p = non significant, Figure
2A). Plasma adrenaline levels showed a similar fluctua-
tion. At rest, hypertensive patients had higher plasma
adrenaline levels but the difference was not significant.
Plasma adrenaline increased during exercise in all three
groups, and at exercise peak was higher in hypertensive
individuals compared to healthy subjects (p < 0.01) and
patients with coronary artery disease (p = non significant,
Figure 2B).
The 6-keto-prostaglandin-F1a levels increased signifi-
cantly (p < 0.05) during exercise in all three groups.
Patients with coronary artery disease had lower plasma
levels of 6-keto-prostaglandin-F1a compared to subjects
from the other two groups and the difference was signifi-
cant only at the peak of exercise compared with healthy
volunteers (p < 0.05, Figure 3A).
Plasma TXB2 levels showed a significant increase during
exercise in all three groups (p < 0.05), reaching their peak
at maximum exercise. There was a trend towards higher
levels at the end of exercise in patients with coronary
artery disease, but there were no significant differences
between the three groups (Figure 3B). Plasma TXB2 levels
remained elevated compared to baseline after 10 min of
rest.
The ratio of 6-keto-prostaglandin-F1a to thromboxane B2
decreased during exercise in all groups, but the decrease
was statistically significant only for the CAD group (p =
0.01). There was no significant difference between the
three groups at rest but at the peak of exercise patients
with CAD had lower 6-keto-prostaglandin-F1a/throm-
boxane B2 ratio compared with healthy volunteers that
almost reached statistical significance (p = 0.053) (Figure
3C). A negative correlation between the PGI2/TXB2 ratio
and platelet aggregation at the end of exercise test with
collagen (p < 0.05) and ADP (p = 0.07) was found in the
group with CAD compared with controls, indicating that
endothelial dysfunction (reduced ratio PGI2/TXB2) con-
tributes to increased platelet aggregation in CAD patients.
Plasma ET-1 levels were higher at baseline in patients with
coronary artery disease compared to healthy volunteers (p
< 0.05), while during exercise ET-1 increased significantly
(p < 0.05) only in hypertensive patients (Figure 3D).
Table 1: Baseline characteristics of patients and healthy volunteers
Healthy volunteers n = 18 Hypertensives n = 26 CAD patients n = 16
Male/Female 15/3 22/4 13/3
Age (y) 33.9 ± 6.2 38.1 ± 6 * 40.9 ± 3.9 *
BMI kg/m2 23.54 ± 2.66 28.35 ± 2.57 * 29.07 ± 4.26 *
SBP mmHg 119.1 ± 8 143.2 ± 14.7 * 138.3 ± 21.9 *
DBP mmHg 79.9 ± 4.8 100.9 ± 4 * 91.4 ± 10.1 *
Heart Rate (/min) 72.7 ± 14.4 82.2 ± 11.9 * 76.4 ± 9.9
* p < 0.05 compared to healthy volunteers
CAD: coronary artery disease
Table 2: Characteristics of patients and healthy volunteers during exercise
Healthy volunteers n = 18 Hypertensives n = 26 CAD patients n = 16
Double Product mmHgxHR/minx10-3 26.2 ± 4 28.3 ± 5.4 26.2 ± 4.4
Heart Rate (beats/min) 72.7 ± 14.4 82.2 ± 11.9 * 76.4 ± 9.9
Peak Heart Rate (beats/min) 163.3 ± 14.6 158 ± 17.2 148.3.4 ± 15.7*
Percentage of maximum HR 85% 85.7% 82.8%
* p < 0.05 compared to healthy volunteers in all other parameters no significant differences were found between the three groups
CAD: coronary artery diseaseBMC Cardiovascular Disorders 2008, 8:11 http://www.biomedcentral.com/1471-2261/8/11
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Platelet aggregation decreased significantly during exer-
cise (p < 0.05) in all groups with the use of ADP and col-
lagen as inducing agents. At exercise peak, normal
volunteers showed significantly greater inhibition of
plasma aggregation when compared with hypertensives
(p < 0.05) and patients with coronary artery disease (p <
0.05) with the use of both ADP and collagen (Figure 4A
and 4B). After 10 min of rest platelet aggregation
remained reduced in healthy volunteers compared to
baseline (p < 0.05), while in hypertensives and patients
with CAD increased and was higher than in healthy vol-
unteers (p < 0.05).
Discussion
Thrombotic events represent the most common and
important complication of atherosclerotic disease. The
clarification of pathophysiologic mechanisms underlying
the thrombotic process seems of utmost importance for
the prevention of such events and the improved manage-
ment of these patients. Our study findings indicate that
patients with coronary artery disease exhibit a thrombotic
tendency compared to healthy subjects during exercise
(increased platelet aggregation compared to healthy indi-
viduals), while hypertensive patients are lying in between
these two groups.
Exercise may induce platelet activation in vivo and
enhanced platelet reactivity in vitro, but results concern-
ing exercise-induced platelet aggregation are far from
unanimous. Much controversy exists regarding platelet
function during SNS activation; studies examining the
results of physical and mental stress on platelet aggrega-
tion in hypertensives and in patients with ischemic heart
disease have shown conflicting results [9-11]. Platelet
responses to exercise depend on several factors, such as
exercise intensity, the exercise protocol used, and physical
fitness. Moreover, measurements of platelet reactivity
either in vitro or ex vivo (aggregability assays) or in vivo
(platelet secretory products, mainly beta thromboglobu-
lin and platelet factor 4) are associated with considerable
methodologic difficulties and thus may account for the
discrepancies of results reported in the literature.
Our findings of decreased platelet aggregation during
exercise despite the increase in plasma catecholamines
seem paradoxical. Increased shear-stress in states of
increased SNS activity results in increased platelet aggrega-
tion, probably mediated by the action of adrenaline, as its
infusion results in increased platelet aggregation in nor-
motensives and hypertensives [12-14]. There is evidence
that the increased platelet aggregation in the early morn-
ing hours is due to increased sensitivity to the action of
adrenaline [15]. The stimulatory effect of epinephrine on
platelet functions has been linked to activation of α2-
adrenoceptor in the membrane of the platelets, since the
effect can be blocked by yohimbine, a specific antagonist
Blood Pressure during exercise in healthy volunteers (A), hypertensives (B) and patients with CAD (C) Figure 1
Blood Pressure during exercise in healthy volunteers (A), hypertensives (B) and patients with CAD (C).
* p<0.05 vs baseline, †p<0.05 vs healthy volunteers.
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A. Noradrenaline levels during exercise in healthy volunteers (A), hypertensives (B) and patients with CAD (C) Figure 2
A. Noradrenaline levels during exercise in healthy volunteers (A), hypertensives (B) and patients with CAD (C). B. Adren-
aline levels during exercise in healthy volunteers (A), hypertensives (B) and patients with CAD (C).
* p<0.05 vs baseline, **p<0.01vs baseline, †p<0.05 vs healthy volunteers, ††p<0.01 vs healthy volunteers.
0
1000
2000
3000
09 1 5 2 5
A
B
C
pg/ml
Time (min)
**
**
†
**
††
**
†
**
††
††
**
†
††
**
†
**
A
0
200
400
600
0 9 15 25
A
B
C
pg/ml
Time (min)
**
††
**
††
**
**
††
**
†
**
††
**
†
**
BBMC Cardiovascular Disorders 2008, 8:11 http://www.biomedcentral.com/1471-2261/8/11
Page 7 of 11
(page number not for citation purposes)
A. 6-keto-Prostaglandin F1a levels during exercise in healthy volunteers (A), hypertensives (B) and patients with CAD (C) Figure 3
A. 6-keto-Prostaglandin F1a levels during exercise in healthy volunteers (A), hypertensives (B) and patients with CAD (C). 
B. Thromboxane B2 levels during exercise in healthy volunteers (A), hypertensives (B) and patients with CAD (C). C. 6-
keto-Prostaglandin F1a /Thromboxane B2 (PGI2/TXA2) ratio during exercise in healthy volunteers (A), hypertensives 
(B) and patients with CAD (C). D. Endothelin-1 levels during exercise in healthy volunteers (A), hypertensives (B) and 
patients with CAD (C).
* p<0.05 vs baseline, **p<0.01vs baseline, †p<0.05 vs healthy volunteers, ††p<0.01 vs healthy volunteers.
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A. Platelet aggregation (with ADP) changes during exercise in healthy volunteers (A), hypertensives (B) and patients with CAD  (C) Figure 4
A. Platelet aggregation (with ADP) changes during exercise in healthy volunteers (A), hypertensives (B) and patients with 
CAD (C). B. Platelet aggregation (with collagen) changes during exercise in healthy volunteers (A), hypertensives (B) and 
patients with CAD (C).
* p<0.05 vs baseline, **p<0.01 vs baseline, †p<0.05 vs healthy volunteers, ††p<0.01 vs healthy volunteers.
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of α2-adrenoceptor [16]; moreover, catecholamines dur-
ing strenuous exercise have been shown to enhance plate-
let activation, facilitate the ability of ADP-activated
fibrinogen receptors, promote fibrinogen binding to
platelet receptors, and more importantly increase the
number of α2-adrenoceptors despite a decrease in their
affinity [17]. Thus, the decreased platelet aggregation
found in our study might be explained by two hypotheses:
a) either noradrenaline that increases much more than
adrenaline (five fold more) during exercise exerts different
effects on platelet aggregation, or b) other factors induced
by physical exercise counter-regulate the negative effects
of adrenaline on platelet aggregation.
Regarding the first hypothesis, experimental studies have
shown increased intra-arterial thrombosis during adrena-
line infusion but decreased thrombosis during noradren-
aline infusion [18]. In addition, prolonged exposure of
platelets to increased adrenaline levels results in decreased
aggregation to adrenaline, probably due to adrenergic
receptor downregulation [19]. There is also evidence that
β2 adrenergic receptor stimulation causes inhibition of
adhesion and aggregation in platelets through increased
NOS activity in platelets [20]. β2  adrenergic receptor-
mediated inhibition of adhesion and aggregation in plate-
lets may partially offset the proaggregatory effects of α2
adrenergic receptor stimulation in response to the endog-
enous catecholamines (noradrenaline and adrenaline).
Regarding the second scenario, noradrenaline has been
reported to be able to stimulate endothelial cells to release
prostacyclin and nitric oxide, both of which are known to
be potent inhibitors of platelet aggregation [21]. In addi-
tion, the increased blood flow during exercise causes
increased shear stress and vasodilatation through the pro-
duction of NO and PGI2[22]. The increased prostacyclin
production, plasma NO metabolites and platelet cGMP
may suppress platelet reactivity [23-25]. All our patients
exhibited increased PGI2 production during exercise, a
potent inhibitor of platelet aggregation. The difference
was significant between healthy volunteers and patients
with coronary artery disease.
Accumulating evidence suggests that platelets of hyperten-
sive patients show signs of activation25 and an increased
tendency to aggregate [27]. Hypertensive patients showed
higher urinary excretion rate of 11-dehydro-TXB2 com-
pared with normotensive controls [28]. Furthermore,
exercise is associated with increased TXA2 production [29-
31]. On the other hand, products of platelet activation
(serotonin, TXA2, ADP) directly increase platelet aggrega-
tion. At the same time, these agents act on endothelial
cells and cause further release of prostacyclin and NO and
inhibit platelet aggregation2. During exercise TXB2 pro-
duction was increased in all groups, more in patients with
coronary artery disease and less in healthy volunteers but
the difference was not statistically significant. The balance
between PGI2 and TXA2, as expressed by the ratio of 6-
keto-prostaglandin-F1a to thromboxane B2 was changed
in favour of the prothrombotic TXA2 in patients with
CAD, that exhibit the higher degree of endothelial dys-
function.
Increased endothelin-1 levels during exercise may contrib-
ute to the pathogenesis of acute myocardial infarction that
sometimes follows vigorous physical exercise. Even small
increments of ET-1 may facilitate vasoconstrictive
responses of coronary vessels to other stimuli. Although
ET-1 generation de novo requires several hours there is
evidence that ET-1 is stored within internal storage vesi-
cles of endothelial cells, and its secretion is a rapid process
with the formation and transit time of a vesicle to the
plasma taking approximately 10 min. This could explain
the abnormal ET-1 synthesis and release during exercise in
our patients with hypertension [32]. The fact that only
hypertensive patients exhibited an increase in ET-1 is
probably explained by the fact that known mechanisms of
ET-1 secretion, as increased SNS activity, pressure and
shear stress [33] were higher during exercise in hyperten-
sive patients. Experimental data concerning ET-1 effects
on platelet function are contradictory showing decreased
[34], increased [35] or unchanged [36] platelet aggrega-
tion. The increased levels of ET-1 in hypertensives and
patients with coronary artery disease are consistent with
the endothelial dysfunction present in these patients and
the role of ET-1 in cardiovascular disease.
Endothelial dysfunction is characterized by a reduction in
prostacyclin and NO, probably resulting in a thrombo-
genic vascular environment that allows thrombus forma-
tion induced by exposure of highly thrombogenic
substances from ruptured or erosive plaques. Even though
the differences were not statistically significant, healthy
individuals had higher PGI2 and lower TXA2 levels, while
patients with coronary heart disease had lower PGI2 and
higher TXA2. The negative correlation between the PGI2/
TXA2 ratio and platelet aggregation in CAD patients indi-
cates that endothelial dysfunction contributes to the
thrombotic tendency in these patients.
A major limitation of our study is that normotensives are
younger and leaner than the other two groups, and
despite their abstinence of regular exercise this may have
influenced favourably their response to exercise. Although
evidence regarding the relationship between obesity and
platelet aggregation are contradictory [37], data from the
Northwick study suggest that obesity (body weight or
body mass index) is not associated with platelet aggrega-
tion in a large sample of about 1000 subjects [38].
Another important limitation of our study is the lack ofBMC Cardiovascular Disorders 2008, 8:11 http://www.biomedcentral.com/1471-2261/8/11
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oxygen consumption estimation during exercise in order
to evaluate exercise intensity; however, the use of the dou-
ble product and the percentage of maximum heart rate
achieved at exercise peak as indirect indices of oxygen con-
sumption (revealing a comparable exercise intensity in
the three groups) overcomes this limitation. Finally, in
our study, NO metabolites and platelet aggregation after
adrenaline induction were not determined; we believe
that the evaluation of these parameters, in a clinical set-
ting similar to ours, will significantly contribute to the
clarification of the mechanisms underlying thrombosis in
CAD, thus representing an excellent idea for further
research in this area.
Conclusion
In summary, platelet aggregation was inhibited during
exercise in healthy individuals, hypertensives and patients
with coronary artery disease. This inhibition of platelet
aggregation probably represents a protective endothelial
mechanism through the production of PGI2  and NO.
Endothelial dysfunction is probably responsible for the
smaller inhibition of platelet aggregation during exercise
in patients with coronary artery disease and hypertensives
compared to healthy subjects. The negative correlation
between the PGI2/TXA2 ratio and platelet aggregation in
CAD patients indicates that endothelial dysfunction con-
tributes to the thrombotic tendency in these patients.
Other causes as defective intraplatelet NO production or
resistance of platelets to the action of NO cannot be
refuted.
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